SmithKline Beecham's Paxil

Supplemental NDA for generalized anxiety disorder is filed April 28. The company says that paroxetine is the first selective serotonin reuptake inhibitor submitted to the FDA for the treatment of GAD, which affects an estimated 14 mil. Americans. The condition is characterized by exaggerated tension and worry that interfere with daily function for at least six months